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Abstract
Background: Ustekinumab (Stelara®), a human monoclonal antibody targeting the p40-subunit of interleukin (IL)-12
and IL-23, is indicated for moderate to severe plaque psoriasis and psoriatic arthritis. In large multicenter,
prospective trials assessing efficacy and safety of ustekinumab increased rates of severe infections have not been
observed so far.
Case presentation: Here, we report the case of a 64-year old woman presenting with chills, pain and swelling of
her right foot with dark maculae at the sole, and elevated inflammatory markers. She had received a third dose of
ustekinumab due to psoriatic arthritis three days before admission. Blood cultures revealed growth of
Staphylococcus aureus and imaging showed a thickening of the aortic wall ventral the bifurcation above the right
internal iliac artery, resembling an acute bacterial endarteritis. Without the evidence of aneurysms and in absence of
foreign bodies, the decision for conservative management was made. The patient received four weeks of antibiotic
therapy with intravenous flucloxacillin, followed by an oral regime with levofloxacin and rifampicin for an additional
four weeks. Inflammatory markers resolved promptly and the patient was discharged in good health.
Conclusion: To our knowledge, this is the first report of a severe S. aureus infection in a patient receiving
ustekinumab. Albeit ustekinumab is generally regarded as a safe drug, severe bacterial infections should always be
included in the differential diagnosis of elevated inflammatory markers in patients receiving biologicals as these
might present with nonspecific symptoms and fever might be absent. Any effort to detect deep-seated or
metastatic infections should be made to prevent complications and to secure appropriate treatment. Although
other risk factors for an invasive staphylococcal infection like psoriasis, recent corticosteroid injection, or prior
hospitalisations were present, and therefore a directive causative link between the S. aureus bacteraemia and
ustekinumab can not be drawn, we considered the reporting of this case worthwhile to alert clinicians as we
believe that ongoing pharmacovigilance to detect increased risks for rare but severe infections beyond phase II and
phase III trials in patients treated with biologicals is essential.
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Background
Staphylococcus aureus is one of the most common
causative organisms of community-acquired or healthcare-
associated bloodstream infections (BSI) [1, 2]. Inhouse
mortality of S. aureus bacteremia (SAB) is considerably
high (20–30 %) [3]. According to a population based study,
patients with severe psoriasis have a higher risk for serious
infections with significantly more hospitalizations for skin
infections [4] compared to the reference population.
Moreover, patients with psoriasis are more frequently
colonized with S. aureus than the normal population, yet
are not regarded as particularly susceptible to S. aureus
infections, which may be due to a pronounced induction
of innate defense antimicrobial peptides in psoriatic skin
lesions [5, 6]. However, a small study reported the occur-
rence of S. aureus bacteremia in patients with extensive
disease i.e. erythrodermic psoriasis [7].
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A large prospective study in France in patients receiv-
ing TNF-α antagonists mainly due to rheumatoid or
psoriatic arthritis, found S. aureus as the dominant
causative pathogen of BSI, including all recorded deaths
and intensive care admissions. The majority of patients
with S. aureus BSI experienced subsequent osteoarticular
manifestations (63 vs. 4 % in BSI patients due to other
pathogens) [8].
Ustekinumab is a human monoclonal antibody that
binds to the p40-subunits of interleukin (IL)-12 and
IL-23 thereby preventing binding of these cytokines to
their respective receptors and inhibiting T cell activa-
tion. Ustekinumab was approved by the FDA and
EMA in 2009 for the treatment of adult patients with
moderate to severe plaque psoriasis as well as patients
with active psoriatic arthritis alone or in combination
with methotrexate.
Like other immunosuppressive agents, ustekinumab
may potentially increase the risk for acquiring infections
or predispose to unusual or particularly severe manifes-
tations of infections or to activate latent infections.
Product labels of ustekinumab include warnings of serious
infections and advise not to start the therapy during clinic-
ally important infections, to stop its application in case a
serious infection develops and to use it with caution in
patients with chronic or recurrent infections. A pre-
treatment tuberculosis screen is recommended. However,
in large multicenter trials infection rates were not elevated
compared to other biologicals or non-biological immuno-
suppressive agents [9–14].
In the following article we report the case of a 64-
year old woman receiving ustekinumab due to psori-
atic arthritis who developed S. aureus bacteremia with
iliac artery endarteritis.
Case presentation
A 64-year old Caucasian woman presented in March
2014 to the emergency department with severe pain and
swelling of her right foot. She also noticed small, dark
lesions on the sole of her right foot. She denied fever
but reported chills for several days (timeline see Fig. 1).
No other symptoms were present. She had a history of
plaque psoriasis and psoriatic arthritis since 2010. In the
past she had received etanercept (stopped in 2010), ada-
limumab (stopped 2011), cyclosporine (stopped February
2013) and golimumab (stopped Oktober 2013) without
significant clinical improvement. She was started on
ustekinumab (45 mg subcutanously) in March 2014,
received the second dose in April and the third dose
three days before hospitalisation. One day before presen-
tation, she had received a steroid injection in the right
sacroiliac joint because of aggravation of pain in the
lumbosacral region. Her medical history was remarkable
for an alcohol induced liver cirrhosis (Child-Pugh stage
B), arterial hypertension and breast cancer (stage pT1c,
pN1a, M0; resection and radiation in 2006, since then in
remission). On admission, the patient was afebrile
(36.8 °C) and the vital signs were within normal ranges
(blood pressure 140/80 mmHg, pulse 87/min). The
clinical examination revealed swelling of her right ankle
and multiple non-elevated dark maculae on the sole of
her right foot (Fig. 2a and b) resembling Janeway
lesions. All joints were tender on palpation with par-
ticular pain in the right sacroiliac joint. Multiple psori-
atic lesions were present. Laboratory analysis revealed a
leukocytosis of 23 × 10 [9] cells/L, a reduced platelet
count of 66 × 10 [9] cells/L, a C-reactive protein level
of 154 mg/L [<5 mg/L], a procalcitonin of 4.67 ng/mL
[<0.5 ng/mL], a blood urea nitrogen of 93 mg/dl, a
serum creatinine of 1.16 mg/dl and an INR 1.35. A CT
scan on the day of admission showed no signs of arth-
ritis, joint effusion or empyema in the right ankle joint.
However, edema and thickening of the aortic/right
common iliac artery wall at the aortic bifurcation,
consistent with an inflammatory vascular lesion, was
noted (Fig. 3a and b). Without an unambiguous focus
(and prior to the CT scan) the patient had been started
on an empiric antibiotic therapy with intravenous
piperacillin/tazobactam (4.5 g every 8 h) and oral clari-
thromycin (500 mg/d). The next day, the patient’s
condition improved. Blood cultures yielded growth of S.
aureus (susceptible to methicillin, fluoroquinolones,
clindamycin and rifampicin). Antibiotic treatment was
modified to intravenous flucloxacillin (4 g every 8 h).
Transesophageal echocardiography revealed no evidence
for infective endocarditis. Rheumatoid factor was negative
and the urine analysis did not show signs of proteinuria or
hematuria. A follow-up CT scan 12 days later confirmed
arterial wall thickening at the aortic bifurcation with a soft
tissue cuff above the right common iliac artery with no
evidence for progression. An additional FDG-PET/CT
scan demonstrated increased metabolism in this vessel
segment (Fig. 4a-c). Apart from moderate inflammatory
activity in the right sacroiliac joint no other hypermeta-
bolic foci were detected.
The patient was treated for four weeks with intravenous
flucloxacillin and was discharged with an oral regime
consisting of levofloxacin (500 mg/d) and rifampicin
(450 mg twice daily) for another four weeks. One month
after completion of the antibiotic therapy the patient was
well with no signs of active infection or recurrence. A
report was filed with the Federal Institute for Drugs and
Medical Devices (BfArm).
Conclusions
To our knowledge, this is the first published report of
a severe S. aureus infection in a patient receiving
ustekinumab. Ustekinumab is a rather new biological
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immunosuppressive agent that is used in moderate to
severe plaque psoriasis and otherwise unresponsive active
psoriatic arthritis. Its efficacy and safety has been studied in
a multicenter, prospective, disease-based registry (Psoriasis
Longitudinal Assessment and Registry [PSOLAR]) [12] as
well as in multiple large multicenter trials [10, 13–16].
Ustekinumab is considered to be well tolerated, most ad-
verse events are mild and do not require dosage adjustment
or cessation of therapy [17]. Clinical trial data available so
far indicate no increased incidence of severe infections
compared to placebo or other biologicals and no specific
patterns of infection could be observed [9, 11–13, 17, 18].
The PSOLAR registry included 4134 patients receiving
ustekinumab. The cumulative incidence for serious infec-
tions was 0.95/100 patient years compared to 1.26 for non-
biologicals and 2,78 for infliximab.
IL-12 plays an important role for the optimal produc-
tion of IFN-γ by T cells and NK cells [19]. Patients with
an inherited defect in the IFN-γ/IL-12 pathway show a
decreased IFN-γ production due to a disturbed inter-
action between phagocytes and T lymphocytes and an
increased susceptibility to infections with microorgan-
isms of the genera Mycobacterium and Salmonella
[20–22]. Severe S. aureus infections have not been
documented so far in such patients or patients receiv-
ing ustekinumab. Of note, IL-23 stimulates Th-17 cell
development. Recent evidence suggests that Th-17 cells
contribute to cutaneous defense against S. aureus [23].
As ustekinumab indirectly inhibits Th-17 pathways this
may be regarded as a theoretical and of course purely
speculative explanatory model for a propensity/higher
susceptibility for S. aureus infections. In general, patients
receiving biologicals and other immunosuppressive agents
for the treatment of rheumatologic disorders may be at
increased risk for severe infections due to different rea-
sons. In addition to the immunsupressive treatment, these
patients are frequently exposed to injections for applica-
tion of drugs but also for diagnostic or therapeutic intraar-
ticular punctures. Moreover, psoriatic skin lesions have
been shown to be more frequently colonized by S. aureus
than healthy skin [24]. In our case of a healthcare-
associated S. aureus bacteremia the portal of entry re-
mains unclear. Potential entry sites include psoriatic skin
lesions or intravascular catheters (which were present
during previous hospitalisations). The inflammatory ero-
sive changes of joints seen in psoriatic (or rheumatoid)
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Fig. 2 Multiple dark maculae on the sole of the right foot
resembling septic emboli/Janeway lesions
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Fig. 3 a and b CT scan showing an aortic wall thickening at the aortic bifurcation with a soft tissue cuff above the right common iliac artery
consistent with endarteritis
Fig. 4 a-c FDG-PET/CT scan showing increased metabolism at the soft tissue cuff above the right common iliac artery
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arthritis may represent an independent risk factor for
osteoarticular infections, as increased adherence to in-
flammatory altered joint surfaces likely accentuates
seeding of pathogens such as S. aureus [25–27].
However, we found no clear evidence for S. aureus
infection of the sacroiliac joint secondary to injection
therapy. Moreover, extension from a contiguous focus
was considered highly unlikely as surrounding tissue was
without pathological findings in several radiological
examinations.
Endarteriitis as seen in our case represents a rare diag-
nosis in the absence of endovascular prosthesis or preex-
isting aneurysm. However, hematogenous seeding in the
endothelium of an otherwise intact arterial intima during
bacteremia may occur and S. aureus is the predominant
pathogen in this context. Our patient had a number of
risk factors that might have contributed to the observed
severe infection like psoriatic lesions, injection therapy
and pior hospitalizations. Besides ustekinumab, our pa-
tient had received a number of different immunosup-
pressive drugs in the past, however, the latest 5 month
prior to the reported infection. Of course, in these com-
plex clinial setting, it is not possible to unambiguously
assign ustekinumab as the underlying cause for this
infection and this is not the intention of our report.
However, we believe that in terms of pharmacovigilance,
reporting of such cases is important.
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